We are a private, clinical-stage biotechnology company focused on the discovery and development of treatments for peripheral neuropathies, including diabetic peripheral neuropathy, chemo and HIV-induced peripheral neuropathy, and others. We are currently studying our lead drug, WST-057, in a Phase 2 clinical trial in Canada for the treatment of human patients with diabetic peripheral neuropathy. Leading stakeholders in the field, including the Juvenile Diabetes Research Foundation, National Institute of Diabetes and Digestive and Kidney Diseases (at the National Institutes of Health) and the Canadian Institutes of Health Research, have supported our research. We are headquartered in San Diego, California.
Investor FAQs
We are headquartered at 7220 Trade St., Ste. 370, San Diego, CA 92121.
Since we are a private company, the only way to purchase stock is to be an accredited investor and to make the investment directly from the company. If you are an accredited investor and are interested, please contact our investors department by contacting (323) 813-8135 or info@winsantor.com.
To see if you are an accredited investor, visit investor.gov.
Wilson Sonsini is our legal counsel.
An archive of our press releases can be viewed on our publications page.
You can submit queries to our investors department by contacting (323) 813-8135 or emailing info@winsantor.com.
